Related Experiment Video
Updated: Apr 23, 2026

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
Published on: January 7, 2019
Electroconvulsivotherapy augmentation with folate in the treatment of a resistant depression
Fayçal Mouaffak1, Alix de Premorel, Haifa Helali
1*Department of Psychiatry, Bicêtre University Hospital; and †Paris-Sud University, AP-HP, INSERM, Paris, France.
Abstract:
Depression is a severe and heterogeneous disorder resulting from interacting genetic, environmental, and epigenetic factors. Nutrient deficiency resulting from bariatric bypass surgery has been involved in the pathophysiological mechanisms of depression and treatment response.We report the case of a patient who developed, after a bariatric bypass surgery, a severe depressive episode, refractory to both pharmacological treatment and electroconvulsivotherapy (ECT). Folate deficiency was evidenced. A dramatic response to ECT was observed after folate supplementation. We focused on the involvement of folate in the pathophysiological mechanisms of depression and response to both pharmacological treatment and ECT. We emphasize on the need for close monitoring of patients experiencing psychiatric disorder (in particular, depressive unipolar disorder) after bariatric surgery.
More Related Videos
08:20MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
Published on: August 11, 2015
09:07Electroconvulsive Seizures in Rats and Fractionation of Their Hippocampi to Examine Seizure-induced Changes in Postsynaptic Density Proteins
Published on: August 15, 2017
Related Concept Videos
Electroconvulsive Therapy
Antidepressant Drugs: MAOIs and Other Agents
Antiepileptic Drugs: Glutamate Antagonists
Psychosis: Goals of Pharmacotherapy
Antiepileptic Drugs: GABAergic Pathway Potentiators
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...